CoChat

The effect of acute vs chronic treatment with P–adrenoceptor blockade on exercise performance, haemodynamic and metabolic parameters in healthy men and women

GULLESTAD, LARS, HALLEN, JOSTEIN, MEDBØ, JON I., GRØNNERØD, OLE, HOLME, INGAR, SEJERSTED, OLE M. · 1996 · British Journal of Clinical Pharmacology
Cited by 40

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

1 Variable results have been reported on the effect of β‐adrenoceptor blockers on maximal oxygen uptake (Vo2 max) and exercise endurance. This may in part be due to different subject populations, but it could also be due to an adaption of metabolic and haemodynamic responses to exercise during chronic treatment with β‐adrenoceptor blockers. The present study was therefore carried out to examine the effect of acute and chronic administration of the non‐selective β‐adrenoceptor blocker propranolol on both peak Vo2 and exercise performance in the same subjects. Since the effect of β‐adrenoceptor blockade has not been properly investigated in women, eight healthy women were compared with seven men. Progressive bicycle exercise to exhaustion was performed after propranolol 0.15 mg kg‐1 i.v. (acute) or 80 mg three times daily for 2 weeks (chronic) or placebo given according to a double‐blind crossover design. 2 Mean (s.e. mean) peak Vo2, was significantly reduced from 42.3 (1.6) ml min‐1 kg‐1 during placebo to 40.3 (1.2, P <0.05)ml min‐1 kg‐1 after acute and 39.1 (1.2, P <0.001) ml min‐1 kg‐1 after chronic propranolol treatment. No significant difference in peak Vo2, between the two propranolol treatment regimens was observed (mean difference 1.2, 95% CI ‐0.1 to 2.4 ml min‐1 kg‐1). There was no treatment interaction with gender. 3 Cumulative work, 163 (9.3) kJ, was significantly reduced by acute, 148 (7.7, P <0.001) kJ, and chronic, 147 (7.6, P <0.001) kJ, administration of propranolol since the time to exhaustion was reduced by 5.3% and 5.3%, respectively. There was no significant difference between the two regimens of propranolol (mean difference 0.2, 95% CI ‐6.7 to 7.0 kJ) or between the sexes. Maximal knee extensor and handgrip strengths were not affected by propranolol. 4 Whereas sex did not influence ventilatory, haemodynamic or metabolic parameters, some differences were observed between acute and chronic propranolol treatment. During submaximal exercise oxygen uptake was reduced by approximately 2% and RER values increased by 0.04‐0.05 after chronic treatment in contrast to no effect of acute propranolol treatment. Heart rate and systolic blood pressure were reduced significantly more after chronic compared with acute propranolol treatment; peak heart rate being 186 (2.2), 147 (2.3) and 134 (2.3) beats min‐1, and peak systolic blood pressure being 189 (7), 171 (4) and 161 (4) mmHg after placebo, acute and chronic propranolol administration, respectively. Also the exercise induced rise in potassium and lactate levels were modified differentially; the rise in potassium concentration was less after chronic compared with acute propranolol treatment and lactate levels were reduced only after chronic administration of propranolol. In contrast, ventilation, which was unchanged after propranolol during submaximal exercise, was reduced to similar extent at exhaustion from 108 (6.4) to 97 (7.2) and 96 (5.9)1 min‐1 after acute and chronic propranolol administration, respectively. Diastolic blood pressure and subjective perception of fatigue were similar across the treatment regimens. 5 The study has demonstrated that acute and chronic administration of propranolol result in different haemodynamic and metabolic response to exercise, although endurance and peak oxygen consumption were reduced to the same extent. The response to propranolol was not significantly different between men and women.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2125.1996.tb00159.x

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 40

Metadata

Authors
GULLESTAD, L., HALLEN, J., MEDBØ, J. I., GRØNNERØD, O., HOLME, I., & SEJERSTED, O. M.
Venue
British Journal of Clinical Pharmacology
Publisher
Wiley
Published
1996-01
Volume
41
Issue
1
Pages
57-67
ISSN
  • 0306-5251 (ISSN-L)
  • 1365-2125
OpenAlex
W1986803095
Cited by
40
References
1
FWCI
1.00
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The effect of acute vs chronic treatment with P–adrenoceptor blockade on exercise performance, haemodynamic and metabolic parameters in healthy men and women. https://app.cochat.ai/papers/10.1111/j.1365-2125.1996.tb00159.x
The paper
GULLESTAD, L., HALLEN, J., MEDBØ, J. I., GRØNNERØD, O., HOLME, I., & SEJERSTED, O. M. (1996). The effect of acute vs chronic treatment with P–adrenoceptor blockade on exercise performance, haemodynamic and metabolic parameters in healthy men and women. British Journal of Clinical Pharmacology. https://doi.org/10.1111/j.1365-2125.1996.tb00159.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.